Skip to main content
OpenTrials
Completed

NCT Number: NCT02402153

Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects

The objective of this pilot trial is to demonstrate the safety and the performance of the Hyposafe hypoglycaemia alarm device before conducting clinical trials in type 1 diabetes patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sydvestjysk Hospital

Esbjerg, 6800, Denmark

About this study

  • Safety: To evaluate safety issues related to implantation and use of the Hyposafe hypoglycaemia alarm device.
  • Performance: To evaluate the performance of the Hyposafe hypoglycaemia alarm device.
  • Usability: To obtain information about the subjects use and acceptance of the Hyposafe Hypoglycaemia alarm device.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects
  • Age 18-70 years
  • For female participants: Not pregnant and, if child bearing potential, usage of reliable anti-contraceptive method during the study period

Exclusion criteria

  • Severe cardiac disease
  • History of myocardial infarction
  • Cardiac arrhythmia
  • Previous stroke or cerebral haemorrhage and any other structural cerebral disease
  • Active cancer or cancer diagnosis within the past five years
  • Uraemia defined as s-creatinine above 3 times upper reference value
  • Liver disease defined as s-alanine aminotransferase (s-ALAT) above 3 times upper reference interval
  • Epilepsy
  • Use of antiepileptic drugs for any purposes
  • Clinical important hearing impairment
  • Use of active implantable medical device including
  • Pacemaker and Implantable Cardioverter Defibrillator (ICD-unit)
  • Cochlear implant
  • Use of following drugs
  • Chemotherapeutic drugs of any kind
  • Methotrexate
  • Third generation antipsychotic drugs (aripiprazole, quetiapine, clozapine, ziprasidone, paliperidone, risperidone, sertindole, amisulpride, olanzapine)
  • Abuse of alcohol (defined as consumption of > 250g alcohol (in Danish: 21 "genstande")) per week or abuse of any other neuro-active substances
  • Infection at the site of device-implantation
  • Any haemorrhagic disease
  • Diving (snorkel diving allowed) or parachute jumping
  • Patients that are judged incapable to understand the patient information or who are unlikely to complete the investigation for any reason
  • Persons operating MRI scanners.
  • Persons operating handheld transceivers for communication (e.g. within the police, medical, fire, air traffic control, marine or military).
  • Persons working at broadcast stations for television or FM/DAB radio.
  • Persons performing extreme sport.

Treatment and study plan

Hyposafe device

Device

Subcutaneous EEG recorder for EEG measurements

Primary outcomes

  1. Performance: EEG Recordings - Impedance

    Time frame: 1 month

    The EEG performance was measured as the mean impedance as a function of time. An impedance value below 5 kOhm is considered very good.

  2. Performance: EEG Quality

    Time frame: 1 month

    The power spectrum densities from the two modalities were directly compared on an integer scale from -5 to 5, where "-5" signifies that the scalp EEG was of much higher quality than the subcutaneous. "0" means they were of equal quality and "5" means the subcutaneous signal was of much higher quality

  3. Performance: Continuous EEG

    Time frame: 1 month

    Average time of EEG recordings (hours/day)

Secondary outcomes

  1. Usability: Reported Discomfort During Day While Wearing the Device

    Time frame: 1 month

    The discomfort during the day was recorded by the study subject every day wearing the device. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: There has been no discomfort while wearing the HypoSafe device during day?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).

  2. Usability: Reported Discomfort During Night While Wearing the Device

    Time frame: 1 month

    The discomfort during the night was recorded by the study subject every night wearing the device. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: There has been no discomfort while wearing the HypoSafe device during night?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).

  3. Usability: Reported Discomfort Related to the Implant in the Beginning of the Study

    Time frame: 19±4 days after implantation

    The discomfort was recorded by the study subjects 19±4 days after implantation. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: I have not experienced any implant discomfort the past two days?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).

  4. Usability: Reported Discomfort Related to the Implant at the End of the Study

    Time frame: 51±3 days after implantation

    The discomfort was recorded by the study subjects 51±3 days after implantation. Reported discomfort was evaluated by the following question: "How much do you agree with the following statement: I have not experienced any implant discomfort the past two days?". The scale ranged from 1 to 5 (strongly agree = 5, agree = 4, neutral = 3, disagree = 2, strongly disagree=1).

Sponsors and collaborators

Lead sponsor

UNEEG Medical A/S

Industry

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Mar 30, 2015
Registry last updated
Sep 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.